ConductScience.org, home

Paper22057701

β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Rodríguez-Baño J and 5 others. Clin Infect Dis, 2012. Cited by 291 papers, by iCite.

Cite this record

ConductScience Library. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Papers, record 22057701. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22057701

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
PubMed
Journal
Clin Infect Dis
PubMed
Year
2012
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
291
iCite
Relative citation ratio, by iCite
11.6
iCite
Revised in PubMed
2026-05-18
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rodríguez-Baño JJesús
2Navarro MDMaría Dolores
3Retamar PPilar
4Picón EEncarnación
5Pascual ÁÁlvaro
6Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria GroupGroup

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Amoxicillin-Potassium Clavulanate CombinationMajor topic
Anti-Bacterial AgentsMajor topic
BacteremiaMajor topic
Escherichia coli InfectionsMajor topic
Penicillanic AcidMajor topic
beta-Lactamase InhibitorsMajor topic
Aged
Aged, 80 and over
Escherichia coli
Female
Humans
Male
Middle Aged
Multivariate Analysis
Piperacillin
Piperacillin, Tazobactam Drug Combination
Proportional Hazards Models
Prospective Studies
Spain
beta-Lactam Resistance

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03891433Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing EnterobacteriaceaeBackgroundClinicalTrials.gov
NCT04699981Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?ResultsClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in22057699Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?https://conductscience.org/library/papers/22057699

Source PubMed

Download CSV of comments and corrections

Cited by148

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 291 citations.

PMIDTitleJournalYearIn PapersSource
42867252Impact of inoculum effect on in vitro activity of intermittent and continuous piperacillin-tazobactam infusion against ESBL-producing Escherichia coli in a hollow-fiber infection model.Microbiol Spectr2026https://conductscience.org/library/papers/42867252PubMed
41857435Real-world outcomes and safety of colistin therapy in children with multidrug-resistant gram-negative infections: a nine-year experience.Eur J Pediatr2026https://conductscience.org/library/papers/41857435PubMed
41301622Antibiotics for Intra-Abdominal Infections: When, Which, How and How Long?Antibiotics (Basel)2025https://conductscience.org/library/papers/41301622PubMed
41231468Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA Netw Open2025https://conductscience.org/library/papers/41231468PubMed
41011196Boronate-Based Inhibitors of Penicillin-Binding Proteins: An Underestimated Avenue for Antibiotic Discovery?Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41011196PubMed
40583993Escherichia coli producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.JAC Antimicrob Resist2025https://conductscience.org/library/papers/40583993PubMed
40558193In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing Uropathogenic E. coli.Antibiotics (Basel)2025https://conductscience.org/library/papers/40558193PubMed
40454310β-Lactam/β-Lactamase Inhibitor Combinations Non-Susceptible ESBL-Producing Enterobacteriaceae Bloodstream Infections: An Underestimated Clinical Entity.Infect Drug Resist2025https://conductscience.org/library/papers/40454310PubMed
39442132Optimization of antibiotic use in the intensive care unit: how we do it.Crit Care Sci2024https://conductscience.org/library/papers/39442132PubMed
38864641
No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study.
Microbiol Spectr2024https://conductscience.org/library/papers/38864641PubMed
38851757Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.World J Emerg Surg2024https://conductscience.org/library/papers/38851757PubMed
38680606All-cause and Infection-attributable Mortality Amongst Adults With Bloodstream Infection-a Population-based Study.Open Forum Infect Dis2024https://conductscience.org/library/papers/38680606PubMed
38630105Microbiological Characteristics and Antibiotic Sensitivity in Patients with Nosocomial Spontaneous Bacterial Peritonitis Caused by Escherichia coli: A Multicenter Study.Infect Microbes Dis2020https://conductscience.org/library/papers/38630105PubMed
38534720Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa.Antibiotics (Basel)2024https://conductscience.org/library/papers/38534720PubMed
38257978
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study.
Microorganisms2024https://conductscience.org/library/papers/38257978PubMed
38197416Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.J Antimicrob Chemother2024https://conductscience.org/library/papers/38197416PubMed
37148398Antibiotic stewardship in the ICU: time to shift into overdrive.Ann Intensive Care2023https://conductscience.org/library/papers/37148398PubMed
37104080Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis.Pharmacy (Basel)2023https://conductscience.org/library/papers/37104080PubMed
36830273Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation.Antibiotics (Basel)2023https://conductscience.org/library/papers/36830273PubMed
36750600Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital.Sci Rep2023https://conductscience.org/library/papers/36750600PubMed

See all 148 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22057701

GET https://conductscience.org/api/papers/v1/22057701/cited_by?page=2